Fig. 4From: Antiviral treatment for treatment-naïve chronic hepatitis B: systematic review and network meta-analysis of randomized controlled trialsEvidence network for HBsAg loss for HBeAg-positive patients. ADV adefovir 10 mg daily, ETV entecavir, LAM lamivudine, TBV telbivudine, PLA placebo, TAF tenofovir alafenamide, TDF tenofovir disoproxil fumarate; ETVTDF, LAMADV1, and LAMADV2 code for different combinations of antiviral agents with full details in Additional file 3Back to article page